Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction

Abstract Chronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive Allograft Syndrome (RAS), is the main reason for adverse long-term outcome after Lung Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cecilia Veraar, Jonathan Kliman, Alberto Benazzo, Felicitas Oberndorfer, Maria Laggner, Philipp Hacker, Thomas Raunegger, Stefan Janik, Peter Jaksch, Walter Klepetko, Hendrik J. Ankersmit, Bernhard Moser
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b1d018156f434affb0f33f57f6b74138
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1d018156f434affb0f33f57f6b74138
record_format	dspace
spelling	oai:doaj.org-article:b1d018156f434affb0f33f57f6b741382021-12-02T17:04:06ZPotential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction10.1038/s41598-021-85949-12045-2322https://doaj.org/article/b1d018156f434affb0f33f57f6b741382021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85949-1https://doaj.org/toc/2045-2322Abstract Chronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive Allograft Syndrome (RAS), is the main reason for adverse long-term outcome after Lung Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD phenotypes. Therefore, we sought to find suitable cytokines to distinguish between BOS, RAS and Azithromycin Responsive Allograft Dysfunction (ARAD); and reveal potential similarities or differences to end-stage fibrotic diseases. We observed significantly increased Lipocalin-2 serum concentrations in RAS compared to BOS patients. In addition, in RAS patients immunohistochemistry revealed Lipocalin-2 expression in bronchial epithelium and alveolar walls. Patients with ARAD showed significantly lower Activin-A serum concentrations compared to Stable-LTX and BOS patients. Further, increased serum concentrations of Lipocalin-2 and Activin-A were predictors of worse freedom-from-CLAD in Stable-LTX patients. These biomarkers serve as promising serum biomarkers for CLAD prediction and seem suitable for implementation in clinical practice.Cecilia VeraarJonathan KlimanAlberto BenazzoFelicitas OberndorferMaria LaggnerPhilipp HackerThomas RauneggerStefan JanikPeter JakschWalter KlepetkoHendrik J. AnkersmitBernhard MoserNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cecilia Veraar Jonathan Kliman Alberto Benazzo Felicitas Oberndorfer Maria Laggner Philipp Hacker Thomas Raunegger Stefan Janik Peter Jaksch Walter Klepetko Hendrik J. Ankersmit Bernhard Moser Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
description	Abstract Chronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive Allograft Syndrome (RAS), is the main reason for adverse long-term outcome after Lung Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD phenotypes. Therefore, we sought to find suitable cytokines to distinguish between BOS, RAS and Azithromycin Responsive Allograft Dysfunction (ARAD); and reveal potential similarities or differences to end-stage fibrotic diseases. We observed significantly increased Lipocalin-2 serum concentrations in RAS compared to BOS patients. In addition, in RAS patients immunohistochemistry revealed Lipocalin-2 expression in bronchial epithelium and alveolar walls. Patients with ARAD showed significantly lower Activin-A serum concentrations compared to Stable-LTX and BOS patients. Further, increased serum concentrations of Lipocalin-2 and Activin-A were predictors of worse freedom-from-CLAD in Stable-LTX patients. These biomarkers serve as promising serum biomarkers for CLAD prediction and seem suitable for implementation in clinical practice.
format	article
author	Cecilia Veraar Jonathan Kliman Alberto Benazzo Felicitas Oberndorfer Maria Laggner Philipp Hacker Thomas Raunegger Stefan Janik Peter Jaksch Walter Klepetko Hendrik J. Ankersmit Bernhard Moser
author_facet	Cecilia Veraar Jonathan Kliman Alberto Benazzo Felicitas Oberndorfer Maria Laggner Philipp Hacker Thomas Raunegger Stefan Janik Peter Jaksch Walter Klepetko Hendrik J. Ankersmit Bernhard Moser
author_sort	Cecilia Veraar
title	Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
title_short	Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
title_full	Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
title_fullStr	Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
title_full_unstemmed	Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
title_sort	potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b1d018156f434affb0f33f57f6b74138
work_keys_str_mv	AT ceciliaveraar potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT jonathankliman potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT albertobenazzo potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT felicitasoberndorfer potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT marialaggner potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT philipphacker potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT thomasraunegger potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT stefanjanik potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT peterjaksch potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT walterklepetko potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT hendrikjankersmit potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction AT bernhardmoser potentialnovelbiomarkersforchroniclungallograftdysfunctionandazithromycinresponsiveallograftdysfunction
_version_	1718381868537085952

Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction

Ejemplares similares